Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 3.18B 2.82B 2.64B 2.41B 4.53B 306B 4.59B 31.94B 12.37B 156B 11.93B 11.68B 501B P/E 2026 *
62.9x
P/E 2027 * 19.5x
Enterprise Value 2.89B 2.57B 2.4B 2.19B 4.12B 278B 4.18B 29.04B 11.24B 142B 10.85B 10.62B 455B EV / Sales 2026 *
5.38x
EV / Sales 2027 * 3.7x
Free-Float
98.23%
Yield 2026 *
-
Yield 2027 * -
1 day-4.31%
1 week-3.73%
Current month-4.31%
1 month+6.48%
3 months-2.13%
6 months+4.94%
Current year-12.91%
1 week 25.22
Extreme 25.22
27.64
1 month 23.1
Extreme 23.1
28.29
Current year 19.3
Extreme 19.295
30.75
1 year 19.3
Extreme 19.295
31.77
3 years 1.76
Extreme 1.76
31.77
5 years 1.76
Extreme 1.76
31.77
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2017
Corporate Officer/Principal 71 03/12/2025
Director of Finance/CFO - 15/05/2025
Director TitleAgeSince
Chairman 55 01/12/2019
Director/Board Member 58 01/01/2016
Director/Board Member 74 01/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Sell

General Counsel

-3,674 0.0029%
15/9/26 Exercice

Director

12,922 0.0103%
8/9/26 Sell

General Counsel

-9,989 0.0079%
Change 5-day change 1-year change 3-year change Capi.($)
-4.31%-3.73%+27.99%+376.27% 3.18B
-0.62%-2.71%+39.30%+114.07% 1,025B
-2.30%-4.44%+39.03%+66.07% 623B
-0.63%-1.96%+6.36%+74.38% 459B
-1.03%-2.82%+59.56%+39.69% 355B
-0.29%-3.50%+22.30%+40.17% 336B
-0.14%-1.62%+13.31%+26.23% 270B
-0.37%-4.40%-3.65%+9.59% 247B
-3.38%+0.30%+36.44%+51.54% 220B
-1.04%-1.46%+32.70%+96.82% 183B
Average -1.41%-2.08%+27.33%+89.48% 372.14B
Weighted average by Cap. -1.05%-2.11%+30.35%+69.75%

Financials

2026 *2027 *
Net sales 537M 477M 446M 407M 766M 51.74B 776M 5.4B 2.09B 26.35B 2.02B 1.97B 84.63B 687M 610M 571M 520M 979M 66.14B 992M 6.9B 2.67B 33.68B 2.58B 2.52B 108B
Net income 53.27M 47.31M 44.25M 40.32M 75.91M 5.13B 76.95M 535M 207M 2.61B 200M 196M 8.39B 173M 154M 144M 131M 247M 16.67B 250M 1.74B 674M 8.49B 650M 636M 27.27B
Net Debt -288M -256M -240M -218M -411M -27.77B -417M -2.9B -1.12B -14.14B -1.08B -1.06B -45.42B -638M -566M -530M -483M -909M -61.4B -921M -6.41B -2.48B -31.27B -2.39B -2.34B -100B
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
01/10/26 USD 25.29 -4.31% 1,637,458
30/09/26 USD 26.43 -1.20% 2,391,395
29/09/26 USD 26.75 -2.12% 2,936,918
28/09/26 USD 27.33 +1.52% 3,065,558
25/09/26 USD 26.92 +2.47% 2,039,977
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
25.29USD
Average target price
37.00USD
Spread / Average Target
+46.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARQT Stock